Prediction of Human Pharmacokinetics of E0703, a Novel Radioprotective Agent, Using Physiologically Based Pharmacokinetic Modeling and an Interspecies Extrapolation Approach
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25053047 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Yun-Xuan Ge und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China. Hauptthemen laut MEDLINE: Radiation-Protective Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Project of National Natural Science Foundation of China, National Science and Technology Major Project.
Abstract (Originalsprache)
E0703, a new steroidal compound optimized from estradiol, significantly increased cell proliferation and the survival rate of KM mice and beagles after ionizing radiation. In this study, we characterize its preclinical pharmacokinetics (PK) and predict its human PK using a physiologically based pharmacokinetic (PBPK) model. The preclinical PK of E0703 was studied in mice and Rhesus monkeys. Asian human clearance (CL) values for E0703 were predicted from various allometric methods. The human PK profiles of E0703 (30 mg) were predicted by the PBPK model in Gastro Plus software 9.8 (SimulationsPlus, Lancaster, CA, USA). Furthermore, tissue distribution and the human PK profiles of different administration dosages and forms were predicted. The 0.002 L/h of CL and 0.005 L of Vss in mice were calculated and optimized from observed PK data. The plasma exposure of E0703 was availably predicted by the CL using the simple allometry (SA) method. The plasma concentration–time profiles of other dosages (20 and 40 mg) and two oral administrations (30 mg) were well-fitted to the observed values. In addition, the PK profile of target organs for E0703 exhibited a higher peak concentration (Cmax) and AUC than plasma. The developed E0703-PBPK model, which is precisely applicable to multiple species, benefits from further clinical development to predict PK in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.
- Department of Pharmacology and Toxicology, Beijing Institute of Radiation Medicine, Beijing 100850, China.
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
ORCID-Profile: Zhuo Zhang
Förderung
- Key Project of National Natural Science Foundation of China
- National Science and Technology Major Project
Zitieren
APA
Ge, Y. X., Zhang, Z., Yan, J. Y., Ma, Z. C., Wang, Y. G., Xiao, C. R., Zhuang, X. M., & Gao, Y. (2024). Prediction of Human Pharmacokinetics of E0703, a Novel Radioprotective Agent, Using Physiologically Based Pharmacokinetic Modeling and an Interspecies Extrapolation Approach. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25053047
Vancouver
Ge YX, Zhang Z, Yan JY, Ma ZC, Wang YG, Xiao CR, et al. Prediction of Human Pharmacokinetics of E0703, a Novel Radioprotective Agent, Using Physiologically Based Pharmacokinetic Modeling and an Interspecies Extrapolation Approach. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25053047
BibTeX
@article{Ge2024,
author = {Ge, Yun-Xuan and Zhang, Zhuo and Yan, Jia-Yi and Ma, Zeng-Chun and Wang, Yu-Guang and Xiao, Cheng-Rong and Zhuang, Xiao-Mei and Gao, Yue},
title = {Prediction of Human Pharmacokinetics of E0703, a Novel Radioprotective Agent, Using Physiologically Based Pharmacokinetic Modeling and an Interspecies Extrapolation Approach},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25053047}
}
EUVIMED